Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

June 01, 2016

WILMINGTON, DE and TAMPA, FL – Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new Moffitt Cancer Center research programs over a period of three years. The research programs will be focused on specific blood cancers, including myeloproliferative neoplasms (MPNs), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic myelomonocytic leukemia (CMML). The objective of this alliance is to develop an improved understanding of basic cancer biology in the areas of focus, and interrogate specific therapeutic hypotheses involving Incyte’s proprietary small molecule therapeutics, both as single agents and in combination. 

“Having access to Incyte’s diverse pipeline of targeted cancer therapies represents a unique and exciting opportunity for Moffitt researchers to expand our efforts to advance medical research in oncology and improve medical care for patients with cancer,” said Jarett Rieger, Senior Director of Moffitt’s Office of Innovation and Industry Alliances and Associate General Counsel. “A huge strength of Moffitt is our ability to form inter-disciplinary research teams, and this exciting research alliance, involving numerous faculty members, is a testament to our team science culture.”

Incyte will provide financial support for three research programs over the three year period of the collaboration.

“Incyte and Moffitt are both committed to improving the lives of patients with cancer through the discovery and development of novel medicines. This research alliance will enable new and important research into multiple blood cancers in a manner that both leverages and extends our current drug discovery efforts,” stated Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “We are pleased to expand our growing network of academic collaborations and join forces with the world class investigators from Moffitt to advance the landscape of cancer treatment.”

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.  For additional information on Incyte, please visit the Company’s website at

Follow @Incyte on Twitter at

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. One of the three largest cancer centers in the United States based on patient volume, the Tampa-based facility is one of only 45 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in Florida and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2 million square feet to research and patient care. With more than 5,000 team members, Moffitt has an economic impact in the state of $1.9 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit, and follow the Moffitt momentum on Facebook, Twitter and YouTube.

Incyte Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding the extent and duration of the planned research collaboration with Moffitt and whether the collaboration with Moffitt will achieve its intended goals including advancing the landscape of cancer treatment and improving medical care for patients with cancer.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi and the compounds in Incyte’s pipeline, the results of further research and development, the risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development, other market or economic factors, competitive and technological advances, and other risks detailed from time to time in the Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2016. Incyte disclaims any intent or obligation to update these forward-looking statements.